Journal article
Intravesical Instillation Treatment of Non–muscle-invasive Bladder Cancer
European urology supplements : official journal of the European Association of Urology, Vol.8(7), pp.549-555
2009
DOI: 10.1016/j.eursup.2009.06.009
Abstract
Bacillus Calmette-Guérin (BCG) is a proven and valuable adjunct to transurethral resection (TUR) for decreasing recurrence and progression of non–muscle-invasive bladder cancer (NMIBC). The European Association of Urology (EAU) and American Urological Association (AUA) have similar recommendations for induction and maintenance treatment in patients based on clinical and pathologic risk factors. To most effectively treat this disease, clinicians must be aware of the risk factors for treatment failure, strategies to deal with failures and BCG intolerance, and the appropriate threshold to proceed with radical cystectomy (RC). Combination, alternative, and multimodal intravesical treatments for patients with BCG failure have arisen in recent years, and the outcomes data are reviewed here.
Details
- Title: Subtitle
- Intravesical Instillation Treatment of Non–muscle-invasive Bladder Cancer
- Creators
- Matthew R. Braasch - University of IowaAndreas Böhle - Helios Hospital SchwerinMichael A. O’Donnell - University of Iowa
- Resource Type
- Journal article
- Publication Details
- European urology supplements : official journal of the European Association of Urology, Vol.8(7), pp.549-555
- Publisher
- Elsevier B.V
- DOI
- 10.1016/j.eursup.2009.06.009
- ISSN
- 1569-9056
- eISSN
- 1878-1500
- Language
- English
- Date published
- 2009
- Academic Unit
- Urology
- Record Identifier
- 9984320855402771
Metrics
3 Record Views